- Home
- PETS vs IFRX Comparison
PETS vs IFRX Comparison
Compare PETS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- IFRX
- Stock Information
- Founded
- PETS 1996
- IFRX 2007
- Country
- PETS United States
- IFRX Germany
- Employees
- PETS N/A
- IFRX N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- IFRX Health Care
- Exchange
- PETS Nasdaq
- IFRX Nasdaq
- Market Cap
- PETS 62.8M
- IFRX 65.8M
- IPO Year
- PETS N/A
- IFRX 2017
- Fundamental
- Price
- PETS $3.24
- IFRX $0.79
- Analyst Decision
- PETS Sell
- IFRX Strong Buy
- Analyst Count
- PETS 2
- IFRX 4
- Target Price
- PETS $3.35
- IFRX $7.75
- AVG Volume (30 Days)
- PETS 127.2K
- IFRX 875.8K
- Earning Date
- PETS 08-05-2025
- IFRX 08-07-2025
- Dividend Yield
- PETS N/A
- IFRX N/A
- EPS Growth
- PETS N/A
- IFRX N/A
- EPS
- PETS 0.02
- IFRX N/A
- Revenue
- PETS $247,010,000.00
- IFRX $140,242.00
- Revenue This Year
- PETS N/A
- IFRX N/A
- Revenue Next Year
- PETS N/A
- IFRX $6,309.47
- P/E Ratio
- PETS $189.87
- IFRX N/A
- Revenue Growth
- PETS N/A
- IFRX 30.90
- 52 Week Low
- PETS $2.90
- IFRX $0.71
- 52 Week High
- PETS $6.85
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- PETS 33.34
- IFRX 34.33
- Support Level
- PETS $3.36
- IFRX $0.75
- Resistance Level
- PETS $3.67
- IFRX $0.83
- Average True Range (ATR)
- PETS 0.20
- IFRX 0.05
- MACD
- PETS -0.08
- IFRX -0.00
- Stochastic Oscillator
- PETS 0.00
- IFRX 29.85
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.